Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach

Br J Haematol. 2019 Sep;186(6):e223-e225. doi: 10.1111/bjh.16116. Epub 2019 Jul 26.

Authors

Fabio Guolo^{1

2}, Paola Minetto^{1

2}, Marino Clavio^{1

2}, Maurizio Miglino^{1

2}, Nicoletta Colombo^{1

2}, Antonia Cagnetta^{1

2}, Michele Cea^{1

2}, Riccardo Marcolin^{1

2}, Andrea Todiere^{1

2}, Filippo Ballerini^{1

2}, Marco Gobbi^{1

2}, Roberto Massimo Lemoli^{1

2}

Affiliations

¹ Clinic of Haematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy.
² IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 31348524
DOI: 10.1111/bjh.16116

No abstract available

Keywords: acute leukaemia; minimal residual disease; quantitative PCR.

Publication types

Evaluation Study
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Cytarabine / administration & dosage
Disease-Free Survival
Etoposide / administration & dosage
Female
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute* / blood
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / mortality
Longitudinal Studies
Male
Middle Aged
Mitoxantrone / administration & dosage
Mutation*
Neoplasm Proteins / blood
Neoplasm Proteins / genetics*
Neoplasm, Residual
Nuclear Proteins / blood
Nuclear Proteins / genetics*
Nucleophosmin
Recurrence
Salvage Therapy
Survival Rate

Substances

NPM1 protein, human
Neoplasm Proteins
Nuclear Proteins
Cytarabine
Nucleophosmin
Etoposide
Mitoxantrone

Supplementary concepts

MAV protocol